SYNAPS Dx

SYNAPS Dx is a privately held company focused on the research, development, and commercialization of diagnostics for neurodegenerative diseases and conditions, including Alzheimer's disease. The company offers DISCERN™, the first accurate minimally invasive test for diagnosing Alzheimer's disease (AD) versus other forms of dementia. SYNAPS Dx’s laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) and is qualified to perform high-complexity clinical laboratory testing.